Opinion

Podcast

Exploring Oral Systemic Therapies for Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations

Author(s):

Lauren Miller, MPAS, PA-C,Jayme M Heim, MSN, FNP-BC

Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.

Related Videos
Aflibercept 8 mg Shows Durability at 3 Years in Wet AMD with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center
Investigating Brensocatib, Potential First Treatment for Bronchiectasis, with James Chalmers, MBChB, PhD
Aflibercept 8 mg Noninferior for RVO in QUASAR with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center
AI in Dermatology: Emerging Insights and Diverging Perspectives
Medical Sisterhood: James Del Rosso, DO
5 experts in this video
Related Content
Timothy E. Dribin, MD I Credit: Cincinnati Children’s Hospital Medical Center
February 20th 2025

Expert Panel Develops Consensus Definition, Clinical Tool for Anaphylaxis Care

Chelsie Derman
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
February 15th 2025

Diabetes Dialogue: Omnipod 5 and Medtronic 780G for Type 2 Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Martin Metz, MD, Deputy Director, Head of Translational Research and Clinical Studies, Institute of Allergology, Charite-Universitatsmedizin Berlin, Germany
February 20th 2025

Add-on Remibrutinib Quickly Improves Urticaria Control in CSU

Victoria Johnson
Kidney Compass: Navigating Clinical Trials
February 13th 2025

Kidney Compass: Applying Hierarchical Composite Endpoints in Kidney Disease Trials

Brendon Neuen, MBBS, PhD Shikha Wadhwani, MD, MS
Credit: Adobe Stock/ Africa Studio
February 20th 2025

SPN-820 Fails Phase 2b Trial for Treatment-Resistant Depression

Chelsie Derman
FDA Clears IND Application for Zabalafin Hydrogel Treatment of Atopic Dermatitis
February 20th 2025

FDA Clears IND Application for Zabalafin Hydrogel Treatment of Atopic Dermatitis

Tim Smith
© 2025 MJH Life Sciences

All rights reserved.